Suppr超能文献

[子宫内膜腺瘤样增生及子宫内膜癌中的激素受体状态]

[Hormone receptor status in adenomatous hyperplasia of the endometrium and endometrial carcinoma].

作者信息

Martin R, Lehmann E, Leitsmann H

机构信息

Institut für Klinische Chemie und Laboratoriumsdiagnostik, Karl-Marx-Universität Leipzig.

出版信息

Zentralbl Gynakol. 1990;112(16):1031-8.

PMID:2220177
Abstract
  1. In glandular hyperplasia and endometrial carcinoma a correlation exists between the increased proliferation rate and the rise of the ER/PR-quotient. 2. The decline of both receptor concentrations and the increase of ER/PR-Quotient in the tumor and neighbouring, non-diseased tissue was demonstrated with increasing dedifferentiation, comparing endometrial carcinoma of different stages (G1 and G2, respectively). 3. In adenomatous hyperplasia the two receptors are significantly increased compared to normal cycling and glandular-hyperplastic endometrium, respectively; there the ER/PR-quotient is smaller than 1. After gestagen therapy decrease of both receptor concentrations demonstrates the success of therapy on one hand. On the other hand the higher decrease of PR shows, that duration and success of therapy could be limited temporally. 4. In endometrial carcinoma, especially in case of progression, recurrence and/or metastases, the determination of receptor status could be useful for therapy conception in the individual patient.
摘要
  1. 在腺体增生和子宫内膜癌中,增殖率的增加与雌激素受体(ER)/孕激素受体(PR)比值的升高之间存在相关性。2. 比较不同分期(分别为G1和G2)的子宫内膜癌,随着肿瘤去分化程度增加,肿瘤组织及邻近非病变组织中两种受体浓度均下降,而ER/PR比值升高。3. 在腺瘤样增生中,与正常月经周期和腺体增生性子宫内膜相比,两种受体显著增加;此时ER/PR比值小于1。孕激素治疗后,两种受体浓度下降一方面表明治疗成功。另一方面,PR下降幅度更大,表明治疗的持续时间和成功程度可能在时间上受到限制。4. 在子宫内膜癌中,尤其是在进展、复发和/或转移的情况下,测定受体状态对个体患者的治疗方案制定可能有用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验